These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6261266)

  • 1. Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action.
    Lovisolo PP; Briatico-Vangosa G; Orsini G; Ronchi R; Angelucci R; Valzelli G
    Pharmacol Res Commun; 1981 Feb; 13(2):151-61. PubMed ID: 6261266
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological profile of a new antilipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) II - Antilipolytic and blood lipid lowering activity.
    Lovisolo PP; Briatico-Vangosa G; Orsini G; Ronchi R; Angelucci R
    Pharmacol Res Commun; 1981 Feb; 13(2):163-74. PubMed ID: 7220575
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of lipolysis by nicotinic acid and by acipimox.
    Fuccella LM; Goldaniga G; Lovisolo P; Maggi E; Musatti L; Mandelli V; Sirtori CR
    Clin Pharmacol Ther; 1980 Dec; 28(6):790-5. PubMed ID: 7438693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cyclonicate, a new hypolipemic drug, on lipolysis in vitro.
    Tessari F; Caparrotta L; Gaion RM; Fassina G
    Farmaco Sci; 1981 Dec; 36(12):1029-36. PubMed ID: 6274681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa.
    Stirling C; McAleer M; Reckless JP; Campbell RR; Mundy D; Betteridge DJ; Foster K
    Clin Sci (Lond); 1985 Jan; 68(1):83-8. PubMed ID: 3964732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the mechanism of action of the lipolytic agent 4-(3,4-dimethoxybenzyl)-2-imidazolidinone (Ro 7-2956).
    Dalton C; Quinn JB; Burghardt CR; Sheppard H
    J Pharmacol Exp Ther; 1970 Jun; 173(2):270-6. PubMed ID: 4317534
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of acipimox on the lipolysis rate in subcutaneous adipose tissue of obese subjects.
    Flechtner-Mors M; Jenkinson CP; Alt A; Adler G; Ditschuneit HH
    Diabetes Metab Res Rev; 2001; 17(5):387-90. PubMed ID: 11747144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypersensitivity of adipose tissue to norepinephrine and other lipolytic agents during blockade of free fatty acids (FFA) mobilization.
    Bizzi A; Codegoni AM; Garattini S
    Biochem Pharmacol; 1969 Sep; 18(9):2053-60. PubMed ID: 4310274
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of 5-methylpyrazole-3-carboxylic acid (U-19425) and nicotinic acid on lipolysis in vitro and in vivo and on cyclic-3',5'-AMP phosphodiesterase.
    Kupiecki FP; Marshall NB
    J Pharmacol Exp Ther; 1968 Mar; 160(1):166-70. PubMed ID: 4295670
    [No Abstract]   [Full Text] [Related]  

  • 10. Age related changes in the antilipolytic effects of nicotinic acid in rat adipose tissue.
    Caparrotta L; Fassina G; Gaion RM; Tessari F
    Br J Pharmacol; 1983 Dec; 80(4):663-70. PubMed ID: 6571225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the hypolipidemic effect of fish oil by inhibition of adipose tissue lipolysis with acipimox, a nicotinic acid analog.
    Seböková E; Klimes I; Hermann M; Minchenko A; Mitková A; Hromadová M
    Ann N Y Acad Sci; 1993 Jun; 683():183-91. PubMed ID: 8102515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nicotinic acid on hormone-, theophylline- and dibutyryl cyclic AMP-induced lipolysis and on cyclic AMP phosphodiesterase.
    Nakano J
    Res Commun Chem Pathol Pharmacol; 1970 Nov; 1(6):769-79. PubMed ID: 4332755
    [No Abstract]   [Full Text] [Related]  

  • 13. Different responses of white and brown adipose tissue to drugs affecting lipolysis.
    Bizzi A; Codegoni AM; Lietti A; Garattini S
    Biochem Pharmacol; 1968 Dec; 17(12):2407-12. PubMed ID: 4305303
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of noradrenaline on the intermediate metabolism of brown adipose tissue.
    Beviz A; Mohme-Lundholm E
    Acta Pharmacol Toxicol (Copenh); 1967; 25():Suppl 4:21-2. PubMed ID: 5630929
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential antilipolytic activity of suloctidil.
    Roncucci R; Roba J; Lambelin G; Ferenczi M; Blaton V; Vandamme D; Peeters H
    Naturwissenschaften; 1975 Mar; 62(3):141-2. PubMed ID: 1240601
    [No Abstract]   [Full Text] [Related]  

  • 16. The development of resistance to a potent lipolysis inhibitor, 3-methylisoxazole-5-carboxylic acid.
    Pereira JN; Holland GF
    J Pharmacol Exp Ther; 1967 Aug; 157(2):381-7. PubMed ID: 6039829
    [No Abstract]   [Full Text] [Related]  

  • 17. The lipolytic action of oxyfedrine in the dog.
    Osswald W; Branco D
    Pharmacology; 1971; 5(3):145-52. PubMed ID: 5119003
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of Lipolysis With Acipimox Attenuates Postburn White Adipose Tissue Browning and Hepatic Fat Infiltration.
    Barayan D; Vinaik R; Auger C; Knuth CM; Abdullahi A; Jeschke MG
    Shock; 2020 Feb; 53(2):137-145. PubMed ID: 31425403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the role of adenyl cyclase in the regulation of lipolysis in fasting.
    Brodie BB; Krishna G; Hynie S
    Biochem Pharmacol; 1969 May; 18(5):1129-34. PubMed ID: 5789779
    [No Abstract]   [Full Text] [Related]  

  • 20. Equilibrium between metabolic pathways producing energy: a key factor in regulating lipolysis.
    Fassina G; Dorigo P; Gaion RM
    Pharmacol Res Commun; 1974 Feb; 6(1):1-21. PubMed ID: 4372642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.